Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

magrolimab (ONO-7913)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Gilead, Ono Pharma

Drug class:

CD47 inhibitor

Related drugs:

›

No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	ONO-7913 Sensitive: B - Late Trials ONO-7913 Sensitive : B	ONO-7913 Sensitive: B - Late Trials ONO-7913 Sensitive : B
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	ONO-7913 Sensitive: B - Late Trials ONO-7913 Sensitive : B	ONO-7913 Sensitive: B - Late Trials ONO-7913 Sensitive : B
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	ONO-7913 Sensitive: C2 – Inclusion Criteria ONO-7913 Sensitive : C2	ONO-7913 Sensitive: C2 – Inclusion Criteria ONO-7913 Sensitive : C2
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax + ONO-7913 Sensitive: C2 – Inclusion Criteria venetoclax + ONO-7913 Sensitive : C2	venetoclax + ONO-7913 Sensitive: C2 – Inclusion Criteria venetoclax + ONO-7913 Sensitive : C2
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	ONO-7913 Sensitive: C3 – Early Trials ONO-7913 Sensitive : C3	ONO-7913 Sensitive: C3 – Early Trials ONO-7913 Sensitive : C3
TP53 wild-type	Myelodysplastic Syndrome	TP53 wild-type	Myelodysplastic Syndrome	ONO-7913 Sensitive: C3 – Early Trials ONO-7913 Sensitive : C3	ONO-7913 Sensitive: C3 – Early Trials ONO-7913 Sensitive : C3
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	atezolizumab + ONO-7913 Sensitive: C3 – Early Trials atezolizumab + ONO-7913 Sensitive : C3	atezolizumab + ONO-7913 Sensitive: C3 – Early Trials atezolizumab + ONO-7913 Sensitive : C3
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + ONO-7913 Sensitive: D – Preclinical trastuzumab + ONO-7913 Sensitive : D	trastuzumab + ONO-7913 Sensitive: D – Preclinical trastuzumab + ONO-7913 Sensitive : D